Operating Partners

DFW maintains close working relationships with a group of highly experienced operating executives across industry segments in which the firm has investment interest. These adjunct team members work closely with DFW's investment professionals in sourcing, evaluating and, in many instances, serving as executives and/or board members in DFW portfolio companies.

The core members of the Operating Partner team are independent of, and not controlled by DFW and include:

Kurt A. Brykman

Mr. Brykman is a proven healthcare executive who has built a career on business transformations and turnarounds along with a strong track record of achieving revenue and EBITDA growth. Mr. Brykman's expertise spans product, service and consulting businesses in industries ranging from healthcare to consumer products. He has worked with DFW as an Advisor starting in 2018 and currently serves as a board member for Lotus Clinical Research, a DFW V portfolio company which focuses on conducting clinical trials related to acute and chronic pain. He also serves on the Board of Insight2Profit, a DFW IV portfolio service company focused on delivering EBITDA growth for clients through implementation and management of pricing strategies.

Prior to working with DFW, Mr. Brykman was the CEO of Kinapse, a London based life science company that specializes in worldwide regulatory affairs outsourcing for biopharma companies. Prior to Kinapse, he was the COO of Medpace, a specialty clinical research organization which provides expertise in executing scientifically challenging trials. Prior to that, he spent 9 years as an Officer and divisional President of PAREXEL International, the 3rd largest CRO worldwide, where he successfully ran the PAREXEL Consulting, PAREXEL Medical Communications and PAREXEL Late Phase Clinicals business units.

Early in his career, Mr. Brykman spend over a decade at Schering Plough's large over-the-counter medicines business where he ran the worldwide Coppertone franchise of sunscreens, sunblocks and dermatology-focused products. He received his MBA from the J. L. Kellogg Graduate School of Management at Northwestern University in Chicago and is a graduate of Michigan State University with a BS degree in Mathematics and Business.

Allen L. Finkelstein, DDS

Dr. Finkelstein is an experienced doctor, executive, and entrepreneur. Dr. Finkelstein is the Founder and Chief Executive Officer of Bedford HealthCare Solutions which provides quality and compliance services to both dental providers and dental insurers. Prior to founding Bedford, Dr. Finkelstein served as the Chief Dental Officer of AmeriChoice / United Health Group, insuring millions of lives. Dr. Finkelstein began his career as a Dental Officer in the US Army.

Dr. Finkelstein is a longtime proponent of integrated dental and medical care and has lectured at dental and medical schools and conferences on the subject of early childhood dentistry and the need for Medical/Dental integration to achieve holistic outcome based healthcare. Throughout his successful business career, Dr. Finkelstein has continued to see patients, is licensed in New York and New Jersey, and currently maintains a dental practice, specializing in Periodontal Prosthesis located in Great Neck, New York. In Addition, Dr. Finkelstein has been active in many community activities, including philanthropies and dental outreach programs for the underserved.

Dr. Finkelstein is currently an adjunct Clinical Assistant Professor of Pediatric Dentistry at the College of Dentistry at New York University, a Senior Advisor for Oral Health Strategies, and an adjunct facility member of the Arizona School of Dentistry and Oral Health at Still University. He also serves as a member of the Harvard University School of Dental Medicine Dean’s Advisory Board, a member of the Drexel College of Medicine Student Advisory Board and a member of the Visitor’s Board of the Kornberg School of Dentistry at Temple University.

Dr. Finkelstein is currently a member of the board of CDHA, a DFW V portfolio company focused on pediatric dental industry, and frequently reviews DFW opportunities in dentistry and more broadly in healthcare. Dr. Finkelstein received a Bachelor of Science degree from the University of Pittsburgh and graduated with honors from Temple University School of Dentistry.

Jeffrey W. Kinell

Mr. Kinell is an experienced health care services executive.  He has worked with DFW since January 2014, when he served as interim CEO of Evolution Research Group, a DFW IV portfolio company focused on clinical trials for special populations, and serves as a Board member today.  He also serves on the Board of Children’s Dental Health Associates, a DFW V portfolio company focused on pediatric dentistry.

Mr. Kinell is currently the CEO of Bracket Global, which offers an integrated suite of e-clinical solutions.  Prior to this, he was the CEO of CRI Lifetree, a leading clinical research company focused on special populations.  He also served as the co-CEO of MedOptions, a provider of behavioral health services to nursing homes and assisted living centers.  Prior to that, he was the COO of Comprehensive Neuroscience, which conducted clinical trials in neuroscience.  He has also served as the CFO of Kelson Pediatric, a manager and operator of pediatric clinics, CEO of a dialysis center operator and the CFO of a publicly traded provider of post-acute care services.   Mr. Kinell is a graduate of the University of Vermont.

Virinder Nohria, M.D., Ph.D.

Dr. Nohria is an experienced physician, biotechnology entrepreneur and a drug developer. Dr. Nohria has worked with DFW since 2006, when the Firm became affiliated with Alaven Pharmaceutical, a DFW Pledge Fund investment, where he was a member of the founding team and Chief Medical Officer, Chief Compliance Officer and Executive Vice President.

Previously, Dr. Nohria has worked for Eli Lilly and UCB, where he was critical in the launch of two blockbuster products. Dr. Nohria was Vice President and Chief Medical Officer of Xcel Pharmaceuticals, a specialty pharmaceutical company in neuroscience that was acquired by Valeant International in 2005. At Xcel Dr. Nohria was responsible for acquiring worldwide rights to a phase III product in neuroscience, which he helped develop in to a drug that has now been partnered with a major global pharmaceutical company and launched in most major markets worldwide. Dr. Nohria is a board-certified neurologist with special qualifications in child neurology. He completed his medical training at the University of Cambridge in England. His postgraduate training was completed in the UK and US at Duke University. He also holds a Ph.D. degree in Neuropharmacology.

Dr. Nohria was a Co-Founder and President of Vidara Therapeutics LLC, a prior Fund III specialty pharmaceutical licensing and acquisition platform.  He is an active board member of Sebela Pharmaceutical, a DFW IV portfolio company, and Saol Therapeutics, a DFW V portfolio company.

Michael O’Donnell

Mr. O’Donnell is a talented operating and turnaround executive, with over 30 years of broad experience including business services, outsourcing, manufacturing and technology based companies. Mr. O’Donnell has worked with DFW in several portfolio companies as a due diligence partner, board member and CEO, including Keane, a DFW III portfolio company involved in the unclaimed property industry, and VersaTech Consulting (IT staffing) and Nurses 24/7 (medical staffing), both of which were separate operating entities of VersaTech Holdings, a DFW investment.

Mr. O’Donnell began his career in the audit practice of Deloitte, with subsequent financial, operating and executive leadership positions with The Ultimate Corp., Wechsler Coffee, Sara Lee Corporation, Eastek Corporation and the Food & Beverage Information Exchange. Mr. O’Donnell has a B.S. in Business Administration from St. Francis University (Pennsylvania) and is a Certified Public Accountant.

Louis H. Ray

Mr. Ray has an extensive operating background in the technology and government contracting arena, and works with DFW in sourcing, evaluating and managing companies in the outsourced services field. Mr. Ray previously served as CEO of MATCOM International, a Fund II portfolio company providing IT and engineering services to agencies of the U.S. Federal Government. Mr. Ray grew MATCOM from $14 million to $80 million in revenue, through organic and acquisition efforts, ultimately leading to a successful sale to SI International for a significant gain to DFW’s Limited Partners. Previously, Mr. Ray was a senior operating executive with ManTech International, a global U.S. Federal Government IT services provider, responsible for managing that company’s information technology design and deployment services to the Intelligence community. Mr. Ray studied physics at Yale University.

Mr. Ray was actively engaged with DFW in connection with Information Innovators, Inc. (“Triple-I”) –a Fund IV portfolio company, and currently advises on LRI, a DFW V portfolio company.

David Roscoe

Mr. Roscoe is a seasoned executive with extensive management and governance experience in finance, capital markets, technology, operations and leadership development. Mr. Roscoe has worked with DFW as a board member of Keane since its initial 2009 investment in the company. As a retired Managing Director of JPMorgan, Mr. Roscoe had responsibilities for every global division of JPMorgan operations, including securities processing, custody and clearance, funds transfer, and corporate trust and ADRs. Over his 33 year career at JPMorgan, he held key leadership roles such as Chief Operating Officer of Corporate Risk Management, Head of Emerging Markets Advisory Services, Head of Corporate Training and Development, President of Morgan Securities Services Corporation, and Global Information and Technology Officer. Mr. Roscoe was also active in the leadership of several financial industry utilities, including Depository Trust, National Securities Clearing Corporation, International Securities Clearing Corporation in the US, and Euroclear Clearance Systems in Brussels. He was also seconded by JPMorgan to serve in London as the Founding Executive Director of CLS Service, a global foreign exchange clearing bank.

After JPMorgan, Mr. Roscoe was employed at Bridge Information Systems as EVP, as President and COO, and ultimately as co-CEO. After four years at Bridge, he joined RiskMetrics Group, where he led every division of the company and served as senior advisor to the CEO, with a concentration on leadership development. He also oversaw the merger integration of ISS, a major proxy advisory firm, prior to taking the company public and then selling it to MSCI. Mr. Roscoe received a B.A. in Economics from Yale University, and an M.B.A. from the University of Oregon. He served as an active officer in the US Naval Reserve in the Vietnam era.

Mr. Roscoe was most recently a member of the board of Keane, a DFW III portfolio company involved in the unclaimed property industry, and serves on the company’s audit committee. He is also a director of the BATS Exchange and serves as board chair of The Hastings Center, a leading independent bioethics research organization.

Bruce Tomason

Mr. Tomason is a seasoned operating executive, with extensive experience in healthcare and pharmaceutical services. Mr. Tomason has worked closely over the years with DFW in sourcing and evaluating opportunities across a broad spectrum of service related industries. Mr. Tomason previously was a serial operator with experience in both small entrepreneurial companies and large international organizations. Over his 30 year career, he has invested in and led several specialty pharmaceutical companies, including Alterna, Richwood Pharmaceuticals (acquired by Shire) and Anthrogenesis (acquired by Celgene), and served as the Chairman of the Board at Pozen, a public late stage drug development company.

Mr. Tomason has also served as CEO of the medical management company One-Call Medical. Previously, Mr. Tomason led a management buyout of Evans Healthcare (a subsidiary of Glaxo); Evans was one of Europe’s largest human and animal vaccine companies. Mr. Tomason began his career with Organon, the US pharmaceutical subsidiary of Azko. Mr. Tomason holds an M.B.A. from Columbia University, and an undergraduate degree from Seton Hall, where he currently serves on the Board of Trustees and Board of Regents.

Mr. Tomason was most recently teamed with DFW in the evaluation of the firm’s investment in Copernicus, a DFW III portfolio company. Concurrent with the firm’s investment, Mr. Tomason was named as CEO, and led the organization through a significant growth phase, including the deployment of industry-leading technology, establishment of a robust business development function and establishment of a quality and metric-driven operating culture. Mr. Tomason is actively involved as a director of Superior Controls, a DFW IV portfolio company.

Bala Venkataraman

Mr. Venkataraman is a Founder of Avego Healthcare Capital, an investment firm focused on life sciences and specialty healthcare investing. Mr. Venkataraman is an experienced operating executive in the specialty pharmaceutical industry, and works closely with DFW in sourcing and evaluating opportunities specifically for pharmaceutical and life-sciences services-related companies. DFW has had an affiliation with Mr. Venkataraman since 2005, having successfully teamed up in four acquisition-driven specialty pharmaceutical platform companies – Alaven Pharmaceutical, Vidara Therapeutics, Sebela Pharmaceuticals & Saol Therapuetics. Alaven and Vidara, two of DFW’s most successful private equity investments, were fully exited in 2010 and 2014, respectively. Mr. Venkataraman began his career with Schering Plough and has held business development, corporate and financial positions with EJ Pharma, Scios, Curative Technologies and Sciele (formerly First Horizon Pharma). Mr. Venkataraman holds a M.S. in Organic Chemistry from Case Western Reserve and an M.B.A. from the Wharton School of Business.

Mr. Venkataraman is currently engaged with DFW in seeking specialty pharma investment opportunities as well serving as an investor of Sebela Pharmaceuticals, a DFW IV specialty pharmaceutical acquisition and in-licensing platform, as well as Saol Therapeutics, a DFW V portfolio company focused on rare disease treatments.